Tiopinac (RS 40974)
(Synonyms: 硫平酸; RS 40974) 目录号 : GC31821
Tiopinac (RS 40974) (RS 40974) 是一种二苯并噻吩，是一种具有口服活性的高效抗炎和解热剂。
Cas No.:61220-69-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tiopinac is a highly potent anti-inflammatory, analgesic and anti-pyretic agent.
Tiopinac (0.03-110 mg/kg) has 40 times the antiphlogistic potency of phenylbutazone. The dose required to reduce paw swelling by 30% is approximately 0.5 mg/kg. Tiopinac does not elicit overt side effects at the 20 mg/kg/day dose. Tiopinac causes a dose-related reversal of the decreases body weight caused by the adjuvant disease, the weight of those rats receiving 0.135 and 0.4 mg/kg/day being significantly greater than that of the positive controls. Tiopinac (0.3-30 mg/kg) is highly potent in inhibiting the pain evoked in the yeastinflamed hind paw of the rat[1].
[1]. Rooks WH 2nd, et al. The anti-inflammatory and analgesic profile of 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-acetic acid (tiopinac). Agents Actions. 1980 Jun;10(3):266-73.
Animal experiment: | Female rats, 160-180 g, receive 0.1 mL of a suspension in mineral oil of heatkilled M. butyricum (10 mg/mL) by means of two intradermal injections (0.05 mL each) into the proximal 1/4 of the tail on day 0. When the test agent is studied for its activity versus the development of the arthritic syndrome, it is administered p.o. (0.5 mL vehicle/dose) twice each day (at 9 a.m. and 4 p.m.) for 17 days, beginning on day 1. On day 18 the intensity of the swelling of the four foot pads and tail is determined blindly utilizing a scoring system in which the swelling in the four paws is scored 0-4 for each paw and the tail swelling is scored 0-3. The total maximum score is 19. The body weights and the weights of both hind paws are obtained. This procedure is a modification of a system initially described by PEARSON. |
References: [1]. Rooks WH 2nd, et al. The anti-inflammatory and analgesic profile of 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-acetic acid (tiopinac). Agents Actions. 1980 Jun;10(3):266-73. | |
| Cas No. | 61220-69-7 | SDF | |
| 别名 | 硫平酸; RS 40974 | ||
| Canonical SMILES | O=C(O)CC1=CC=C2C(SCC3=CC=CC=C3C2=O)=C1 | ||
| 分子式 | C16H12O3S | 分子量 | 284.33 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.517 mL | 17.5852 mL | 35.1704 mL |
| 5 mM | 0.7034 mL | 3.517 mL | 7.0341 mL |
| 10 mM | 0.3517 mL | 1.7585 mL | 3.517 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet